Saif Mashaqi1, David Gozal2. 1. Division of Sleep Medicine, University of North Dakota School of Medicine - Sanford Health, Fargo, North Dakota. 2. Department of Child Health and the Child Health Research Institute, University of Missouri School of Medicine, Columbia, Missouri.
Abstract
INTRODUCTION: Obstructive sleep apnea (OSA) and systemic hypertension (SH) are common and interrelated diseases. It is estimated that approximately 75% of treatment-resistant hypertension cases have an underlying OSA. Exploration of the gut microbiome is a new advance in medicine that has been linked to many comorbid illnesses, including SH and OSA. Here, we will review the literature in SH and gut dysbiosis, OSA and gut dysbiosis, and whether gut dysbiosis is common in both conditions. METHODS: We reviewed the National Center for Biotechnology Information database, including PubMed and PubMed Central. We identified a total of 230 articles. The literature search was conducted using the phrase "obstructive sleep apnea and gut dysbiosis." Only original research articles were included. This yielded a total of 12 articles. RESULTS: Most of the research conducted in this field was on animal models, and almost all trials confirmed that intermittent hypoxia models resulted in gut dysbiosis. Gut dysbiosis, however, can cause a state of low-grade inflammation through damage to the gut wall barrier resulting in "leaky gut." Neuroinflammation is a hallmark of the pathophysiology of OSA-induced SH. CONCLUSIONS: Gut dysbiosis seems to be an important factor in the pathophysiology of OSA-induced hypertension. Reversing gut dysbiosis at an early stage through prebiotics and probiotics and fecal microbiota transplantation combined with positive airway pressure therapy may open new horizons of treatment to prevent SH. More studies are needed in humans to elicit the effect of positive airway pressure therapy on gut dysbiosis.
INTRODUCTION:Obstructive sleep apnea (OSA) and systemic hypertension (SH) are common and interrelated diseases. It is estimated that approximately 75% of treatment-resistant hypertension cases have an underlying OSA. Exploration of the gut microbiome is a new advance in medicine that has been linked to many comorbid illnesses, including SH and OSA. Here, we will review the literature in SH and gut dysbiosis, OSA and gut dysbiosis, and whether gut dysbiosis is common in both conditions. METHODS: We reviewed the National Center for Biotechnology Information database, including PubMed and PubMed Central. We identified a total of 230 articles. The literature search was conducted using the phrase "obstructive sleep apnea and gut dysbiosis." Only original research articles were included. This yielded a total of 12 articles. RESULTS: Most of the research conducted in this field was on animal models, and almost all trials confirmed that intermittent hypoxia models resulted in gut dysbiosis. Gut dysbiosis, however, can cause a state of low-grade inflammation through damage to the gut wall barrier resulting in "leaky gut." Neuroinflammation is a hallmark of the pathophysiology of OSA-induced SH. CONCLUSIONS:Gut dysbiosis seems to be an important factor in the pathophysiology of OSA-induced hypertension. Reversing gut dysbiosis at an early stage through prebiotics and probiotics and fecal microbiota transplantation combined with positive airway pressure therapy may open new horizons of treatment to prevent SH. More studies are needed in humans to elicit the effect of positive airway pressure therapy on gut dysbiosis.
Authors: M K Nøhr; K L Egerod; S H Christiansen; A Gille; S Offermanns; T W Schwartz; M Møller Journal: Neuroscience Date: 2015-01-28 Impact factor: 3.590
Authors: Irene Cano-Pumarega; Joaquín Durán-Cantolla; Felipe Aizpuru; Erika Miranda-Serrano; Ramón Rubio; Cristina Martínez-Null; Javier de Miguel; Carlos Egea; Laura Cancelo; Ainhoa Alvarez; Marta Fernández-Bolaños; Ferrán Barbé Journal: Am J Respir Crit Care Med Date: 2011-08-25 Impact factor: 21.405
Authors: Jennifer L Pluznick; Ryan J Protzko; Haykanush Gevorgyan; Zita Peterlin; Arnold Sipos; Jinah Han; Isabelle Brunet; La-Xiang Wan; Federico Rey; Tong Wang; Stuart J Firestein; Masashi Yanagisawa; Jeffrey I Gordon; Anne Eichmann; Janos Peti-Peterdi; Michael J Caplan Journal: Proc Natl Acad Sci U S A Date: 2013-02-11 Impact factor: 11.205
Authors: Benjamin G Wu; Imran Sulaiman; Jing Wang; Nan Shen; Jose C Clemente; Yonghua Li; Robert J Laumbach; Shou-En Lu; Iris Udasin; Oanh Le-Hoang; Alan Perez; Shahnaz Alimokhtari; Kathleen Black; Michael Plietz; Akosua Twumasi; Haley Sanders; Patrick Malecha; Bianca Kapoor; Benjamin D Scaglione; Anbang Wang; Cameron Blazoski; Michael D Weiden; David M Rapoport; Denise Harrison; Nishay Chitkara; Eugenio Vicente; José M Marin; Jag Sunderram; Indu Ayappa; Leopoldo N Segal Journal: Am J Respir Crit Care Med Date: 2019-01-01 Impact factor: 21.405
Authors: Wolfgang Stremmel; Kathrin V Schmidt; Vera Schuhmann; Frank Kratzer; Sven F Garbade; Claus-Dieter Langhans; Gert Fricker; Jürgen G Okun Journal: PLoS One Date: 2017-01-27 Impact factor: 3.240
Authors: Karen M O'Connor; Eric F Lucking; Thomaz F S Bastiaanssen; Veronica L Peterson; Fiona Crispie; Paul D Cotter; Gerard Clarke; John F Cryan; Ken D O'Halloran Journal: EBioMedicine Date: 2020-08-30 Impact factor: 8.143